Dawn Marie Anderson

US Patent:

20120101838, Apr 26, 2012

Filed:

Oct 20, 2010

Appl. No.:

12/908616

Inventors:

Helen Mary Lingard - Cary NC, US
Dawn Michelle Anderson - Raleigh NC, US
Mary Margaret Barbour - Garner NC, US
Rae Ellen McCorkle - Clayton NC, US
Sharon Kinning - Lanark, GB

International Classification:

G06Q 10/00
G06Q 50/00

US Classification:

705 2

Abstract:

Systems and processes for managing and supporting clinical trials and clinical trial operations, more particularly for managing and supporting governmental authority, ethics committee, and/or other regulatory authority notifications and submissions in the context of clinical trials in various countries throughout the world. Such systems and processes leverage the insight that such regulatory authority requirements vary from one country to the next, but that all or essentially all such regulatory authority requirements can be categorized into a limited number of groups as to which a limited number of workflows can be created. Such workflows can be automated and supported with systems and processes according to embodiments of the invention, which can then control sequence of activities to comply with regulations and requirements in the various countries in which a clinical trial occurs.

US Patent:

20120232949, Sep 13, 2012

Filed:

Mar 11, 2011

Appl. No.:

13/046295

Inventors:

Helen Mary Lingard - Cary NC, US
Dawn Michelle Anderson - Raleigh NC, US
Sarah Louise Bass-Charlesworth - Middlesex, GB

International Classification:

G06Q 10/04

US Classification:

705 728

Abstract:

Systems and methods are disclosed for managing information from a feasibility study of a clinical trial protocol. Data relationships in a database can be utilized to, for example, formulate bids for managing a clinical trial protocol, track information about a feasibility study, output reminder notifications regarding overdue documents in connection with the feasibility study, provide information for use in site start-up or other processes implemented in conducting the clinical trial protocol, and allow feasibility study information to be analyzed after a clinical trial protocol has been conducted.